Search Result

Results for "

glutaminase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glutaminase (21) Apoptosis (2) Autophagy (2) Reactive Oxygen Species (1)
By Research Areas:	Cancer (19) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Antibodies

Targets Recommended: Glutaminase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2760

*Glutaminase* GLS	Others	Others Cancer
Glutaminase (GLS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-12682

Glutaminase C-IN-1 5 Publications Verification Compound 968	Glutaminase	Cancer
Glutaminase C-IN-1 (Compound 968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts .

HY-79583

Glutaminase-IN-3 1 Publications Verification	Glutaminase	Cancer
Glutaminase-IN-3 (compound 657) is a potent *glutaminase* inhibitor with an IC₅₀ of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657 .

HY-114334

Glutaminase-IN-1 1 Publications Verification CB839 derivative	Glutaminase	Cancer
Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC₅₀ of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.

HY-103671A

IPN60090 dihydrochloride	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers .

HY-103671

IPN60090	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1?(GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers .

HY-149602

Glutaminase C-IN-2	Glutaminase Reactive Oxygen Species	Cancer
Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC₅₀ of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects .

HY-146658

Glutaminase-IN-4	Glutaminase	Cancer
Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC₅₀ of 2.3 μM .

HY-114929

THDP17	Glutaminase	Neurological Disease
THDP17 is an orally active *glutaminase* inhibitor. THDP17 decreases ammonia production through glutaminase inhibition .

HY-N2916

Barbinervic acid	Glutaminase	Neurological Disease
Barbinervic acid is a *glutaminase* inhibitor with an IC₅₀ of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .

HY-W006187

2-Amino-2-(p-tolyl)acetic acid	Glutaminase	Cancer
2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI) .

HY-12248

Telaglenastat Maximum Cited Publications 70 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and *GAC (glutaminase* C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy** and has antitumor activity .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and *GAC (glutaminase* C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy** and has antitumor activity .

HY-12683

BPTES 30+ Cited Publications	Glutaminase	Cancer
BPTES is an allosteric and selective *glutaminase* inhibitor with an IC₅₀ of 0.16 μM.

HY-148241

A-446	Glutaminase	Cancer
A-446 is a potent glutaminase (GLS) inhibitor with an IC₅₀ value of 31 nM .

HY-122218

JHU-083 4 Publications Verification	Glutaminase	Neurological Disease
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective *glutaminase* antagonist. JHU-083 blocks glutaminase activity in brain CD11b ⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals .

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-152207

LWG-301	Glutaminase Apoptosis	Cancer
LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC₅₀ value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model .

HY-151434

GLS1 Inhibitor-6	Glutaminase Apoptosis	Cancer
GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC₅₀=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .

HY-155138

GLS1 Inhibitor-7	Glutaminase	Metabolic Disease Cancer
GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC₅₀=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties .

HY-158378

Trivalent hydroxyarsinothricn R-AST-OH	Glutaminase	Cancer
Trivalent hydroxyarsinothricn (R-AST-OH) is a covalent and irreversible *kidney-type glutaminase* (KGA)** inhibitor. Trivalent hydroxyarsinothricn binds to the glutamine binding site and forms a covalent bond with an active site cysteine residue. Trivalent hydroxyarsinothricn selectively kills triple-negative breast cancer (TNBC) cells and is not cytotoxic to the control cell line. KGA is the enzyme that controls glutamine metabolism and is correlated with tumor malignancy .

HY-136704

GLS1 Inhibitor-1	Glutaminase	Cancer
GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC₅₀ of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC₅₀ of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI₅₀ of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	973 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 973 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

973 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 973 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

HY-L189

Amino Acid Metabolism Compound Library	227 compounds
Amino acids, as one of the most fundamental organic compounds in living organisms, serve not only as the basic building blocks of proteins but also but also undertake the functions of energy supply, neurotransmitter synthesis, and maintenance of internal environment stability.Amino acid metabolic enzymes are a class of enzymes involved in the metabolic processes of amino acids, catalyzing their synthesis, breakdown, transformation, and interactions with other metabolic pathways. Abnormalities in amino acid metabolic enzymes can lead to various metabolic diseases, such as phenylketonuria and hyperammonemia, etc. Therefore, actively exploring and regulating the processes of amino acid metabolism is crucial for the development of drugs related to these diseases. MCE designs a unique collection of 227 small molecules target amino acid metabolizing enzymes, which is an important tool for studying studying amino acid metabolism processes or metabolism-related drug development.

Amino Acid Metabolism Compound Library

227 compounds

Amino acids, as one of the most fundamental organic compounds in living organisms, serve not only as the basic building blocks of proteins but also but also undertake the functions of energy supply, neurotransmitter synthesis, and maintenance of internal environment stability.Amino acid metabolic enzymes are a class of enzymes involved in the metabolic processes of amino acids, catalyzing their synthesis, breakdown, transformation, and interactions with other metabolic pathways. Abnormalities in amino acid metabolic enzymes can lead to various metabolic diseases, such as phenylketonuria and hyperammonemia, etc. Therefore, actively exploring and regulating the processes of amino acid metabolism is crucial for the development of drugs related to these diseases.

MCE designs a unique collection of 227 small molecules target amino acid metabolizing enzymes, which is an important tool for studying studying amino acid metabolism processes or metabolism-related drug development.

Cat. No.	Product Name	Target	Research Area

HY-W006187

2-Amino-2-(p-tolyl)acetic acid	Glutaminase	Cancer
2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI) .

Barbinervic acid	Structural Classification Ketones, Aldehydes, Acids Source classification Rubiaceae Mitragyna inermis (Willd.) Kuntze Plants	Glutaminase
Barbinervic acid is a *glutaminase* inhibitor with an IC₅₀ of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80690

	Glutaminase Antibody glutaminase kidney isoform; GLS; GLS1; KGA; K-glutaminase; GAM; GAC; glutaminase C; L-glutamine amidohydrolase	WB, ICC/IF, IP	Human, Mouse, Rat
	Glutaminase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 73 kDa, targeting to Glutaminase. It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P81600

	TAX1BP3 Antibody (YA1345) glutaminase interacting protein 3; Tax interaction protein 1; Tax1 binding protein 3; Tax1bp3; TIP1	WB, IHC-P, FC	Human, Mouse, Rat
	TAX1BP3 Antibody (YA1345) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1345), targeting TAX1BP3, with a predicted molecular weight of 14 kDa (observed band size: 14 kDa). TAX1BP3 Antibody (YA1345) can be used for WB, IHC-P, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks